TMCnet - World's Largest Communications and Technology Community



Research and Markets: Strategic Analysis of the Global Anti-Obesity Prescription Pharmaceuticals Market 2014
[May 06, 2014]

Research and Markets: Strategic Analysis of the Global Anti-Obesity Prescription Pharmaceuticals Market 2014

DUBLIN --(Business Wire)--

Research and Markets ( has announced the addition of the "A Strategic Analysis of the Global Anti-Obesity Prescription Pharmaceuticals Market" report to their offering.

Prescription drug therapy for the treatment of obesity is experiencing a revival of interest with new government incentives and the recent approval of two new drugs, with two more pending imminent approval. This research service focuses on the competitive landscape of prescription drugs for the treatment of obesity. A global product and pipeline assessment is provided for marketed and investigational products. Segmentation by drug class is provided along with additional supporting information, such as clinical-trial timelines and results, historical and projected launch timelines, regulatory guidelines for clinical trial design and approval, and global epidemiology by region.

Executive Summary:

  • The FDA recently approved 2 new prescription obesity treatments: Arena Pharmaceuticals' Belviq (partnered with Eisai) launched in June 2013, and Vivus' Qsymia, which became available September 2012. These FDA approvals the first for obesity in more than a decade add new therapeutic options to a market previously comprising a single approved drug: Roche's Xenical.
  • A third new drug, Orexigen's Contrave, is pending FDA approval upon successful demonstration of cardiac safety in an ongoing trial for cardiovascular outcomes and resubmission of the new drug application (NDA) in December 2013. A decision is expected from the FDA June 10, 2014, and in the second half of 2014 from the EMA (News - Alert). All three of these new drugs were initially rejected by the FDA, which sought additional confirmation of an acceptable safety prfile.
  • Approval of the obesity indication for Novo Nordisk's Victoza (liraglutide) could come as soon as mid-2014, closely coinciding with the potential approval of Contrave.
  • Market uptake of Qsymia and Belviq has been below expectations, largely due to insurance reimbursement hurdles and possibly because of physician and patient concerns about safety. Contrave, if approved, may have better uptake in light of its designation as an uncontrolled substance and stronger marketing capabilities of partner Takeda, particularly to the primary care and diabetes communities.
  • Global medical and regulatory communities recognize the urgent need for the pharmacotherapeutic treatment of obesity when lifestyle interventions fail to adequately address excess body fat.
  • While numerous sympathomimetic amine anorectics such as phentermine, benzphetamine, and diethylpropion are available by prescription, association with serious side effects limits their use, and prescribing is mainly limited to bariatric surgeons.
  • The global market potential for safe and effective obesity therapies is significant; however, the discovery and development of efficacious weight-loss drugs that are safe enough for chronic use has proven challenging for even the most capable pharmaceutical and biotech companies.
  • Ongoing research efforts are beginning to shed new light on the pathology of obesity, as recent discoveries of differential gene expression and genetic variants found in the different fat depots advance our understanding of why abdominal fat is more strongly associated with morbidity and mortality compared with subcutaneous adipose tissue. Discoveries such as these could eventually lead to targeted therapies aimed at reducing visceral adiposity.

Key Topics Covered:

1. Executive Summary

2. Methodology and Scope

3. Introduction to the Global Anti-obesity Prescription Drugs Market

  • Obesity Indication Background
  • Historical and Projected Timeline (News - Alert) for Anti-obesity Drugs
  • Potential Prescribing Behavior Scenario
  • Regulators' Recommendations for Designing Anti-obesity Drug Clinical Trials
  • Regional Comparison of Drug Approval Requirements
  • Global Prevalence of Obesity by Region
  • Market Overview: Segmentation

4. Competitive Landscape

  • Anti-obesity Prescription Pharmaceuticals Market: Competitive Landscape
  • Ongoing Phase 3 Trials for Obesity Drugs
  • Ongoing Post-marketing Trials for Obesity Drugs
  • Comparative Efficacy of Obesity Drugs
  • Pivotal Trial Programs of Recently Approved Anti-obesity Drugs
  • Pivotal Trial Programs of Late-stage Anti-obesity Drugs
  • Marketed Products Synopsis (News - Alert)
  • Pipeline Synopsis
  • Qsymia (phentermine/topiramat ER)
  • Belviq (lorcaserin HCl)
  • Contrave (bupropion SR/ naltrexone SR)
  • Victoza (liraglutide)

5. Conclusions and Recommendations

Companies Mentioned

  • 7TM Pharma
  • Akrimax Pharmaceuticals
  • Alizé Pharma
  • Alpex Pharma SA
  • Ami Pharm
  • Angio Lab
  • Arena Pharmaceuticals
  • Arrowhead Research
  • AstraZeneca
  • Bridge BioResearch
  • Boehringer Ingelheim
  • Compellis Pharmaceuticals
  • Yungjin Pharm
  • Zafgen
  • Zealand Pharma
  • Zydus Cadila

For more information visit

[ Back To's Homepage ]

Technology Marketing Corporation

35 Nutmeg Drive Suite 340, Trumbull, Connecticut 06611 USA
Ph: 800-243-6002, 203-852-6800
Fx: 203-866-3326

General comments:
Comments about this site:


© 2018 Technology Marketing Corporation. All rights reserved | Privacy Policy